X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10073) 10073
Newsletter (962) 962
Newspaper Article (373) 373
Magazine Article (86) 86
Book / eBook (24) 24
Book Chapter (10) 10
Publication (6) 6
Dissertation (5) 5
Book Review (4) 4
Conference Proceeding (4) 4
Web Resource (4) 4
Reference (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9127) 9127
male (5099) 5099
female (4672) 4672
middle aged (3953) 3953
diabetes (3773) 3773
aged (3115) 3115
endocrinology & metabolism (2957) 2957
risk factors (2676) 2676
adult (2293) 2293
diabetic angiopathies - drug therapy (1961) 1961
diabetic angiopathies - prevention & control (1944) 1944
diabetes mellitus, type 2 - complications (1834) 1834
diabetic angiopathies - physiopathology (1680) 1680
type 2 diabetes (1585) 1585
research (1502) 1502
diabetic angiopathies - epidemiology (1468) 1468
mortality (1401) 1401
diabetes mellitus (1400) 1400
diabetic angiopathies - therapy (1338) 1338
diabetes mellitus, type 2 - drug therapy (1328) 1328
mellitus (1235) 1235
animals (1224) 1224
diabetic retinopathy (1211) 1211
diabetic angiopathies - etiology (1196) 1196
care and treatment (1174) 1174
diabetics (1154) 1154
diabetic angiopathies - blood (1124) 1124
hypoglycemic agents - therapeutic use (1122) 1122
cardiac & cardiovascular systems (1107) 1107
diabetes mellitus, type 2 - blood (999) 999
cardiovascular disease (962) 962
treatment outcome (949) 949
diabetes mellitus, type 2 - physiopathology (891) 891
blood glucose - metabolism (883) 883
diabetic angiopathies - complications (865) 865
hypertension (848) 848
risk (830) 830
analysis (761) 761
blood pressure (755) 755
diabetic angiopathies - diagnosis (746) 746
disease (736) 736
prevalence (733) 733
health aspects (728) 728
complications (725) 725
diabetes complications (716) 716
diabetes mellitus, type 1 - complications (716) 716
diabetes therapy (715) 715
glucose (712) 712
medicine, general & internal (710) 710
atherosclerosis (699) 699
diabetic angiopathies - mortality (688) 688
diabetic foot (679) 679
medical research (675) 675
insulin - therapeutic use (671) 671
time factors (667) 667
cardiovascular-disease (663) 663
insulin (650) 650
peripheral vascular disease (650) 650
cardiovascular diseases (637) 637
medicine & public health (627) 627
follow-up studies (626) 626
oxidative stress (623) 623
cardiovascular diseases - prevention & control (621) 621
risk-factors (613) 613
medicine, experimental (593) 593
hypertension - drug therapy (584) 584
aged, 80 and over (581) 581
complications and side effects (575) 575
adolescent (568) 568
diabetic angiopathies - metabolism (560) 560
diabetic angiopathies (551) 551
prospective studies (551) 551
internal medicine (541) 541
hyperglycemia (537) 537
insulin resistance (529) 529
diabetic angiopathies - pathology (525) 525
prognosis (515) 515
diabetes mellitus - drug therapy (506) 506
cardiovascular diseases - epidemiology (489) 489
rats (473) 473
prevention (472) 472
type 1 diabetes (468) 468
glycated hemoglobin a - analysis (465) 465
retrospective studies (461) 461
coronary-heart-disease (460) 460
antihypertensive agents - therapeutic use (446) 446
diabetes mellitus, type 2 - therapy (441) 441
glycated hemoglobin a - metabolism (438) 438
myocardial-infarction (438) 438
insulin-resistance (428) 428
cohort studies (418) 418
diabetes mellitus, type 2 - epidemiology (414) 414
drug therapy (412) 412
diabetic angiopathies - surgery (411) 411
hypertension - complications (405) 405
cross-sectional studies (402) 402
diabetes mellitus, type 1 - blood (399) 399
surgery (398) 398
risk assessment (396) 396
biomarkers - blood (395) 395
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10021) 10021
German (446) 446
French (294) 294
Russian (238) 238
Japanese (162) 162
Italian (131) 131
Spanish (80) 80
Polish (53) 53
Czech (41) 41
Chinese (30) 30
Portuguese (24) 24
Swedish (22) 22
Hungarian (17) 17
Danish (16) 16
Ukrainian (15) 15
Romanian (13) 13
Croatian (11) 11
Dutch (9) 9
Norwegian (9) 9
Bulgarian (8) 8
Finnish (8) 8
Hebrew (6) 6
Serbian (6) 6
Slovak (5) 5
Korean (1) 1
Lithuanian (1) 1
Romansh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMJ : British Medical Journal, ISSN 0959-8138, 6/2015, Volume 350, Issue jun22 1, pp. h3234 - h3234
Journal Article
BMJ, ISSN 0959-8138, 9/2018, Volume 362, p. k3359
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9786, pp. 156 - 167
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 243, Issue 2, pp. 438 - 448
Abstract Objective The circulating irisin increases energy expenditure and improves insulin resistance in mice and humans. The improvement of insulin... 
Cardiovascular | Irisin | AMPK | Diabetes mellitus | Atherosclerosis | Endothelium | APOPTOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | CHOLESTEROL | PHOSPHORYLATION | NITRIC-OXIDE SYNTHASE | CIRCULATING IRISIN | KINASE-C | CORONARY-ARTERY | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | CELL | ASSOCIATION | Diabetes Mellitus, Experimental - drug therapy | Apolipoproteins E - deficiency | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Atherosclerosis - genetics | Diabetes Mellitus, Experimental - genetics | Endothelium, Vascular - drug effects | Male | Diabetic Angiopathies - physiopathology | RNA Interference | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Diabetic Angiopathies - prevention & control | Proto-Oncogene Proteins c-akt - metabolism | Cytokines - genetics | Cytoprotection | Diabetes Mellitus, Experimental - physiopathology | Atherosclerosis - pathology | Fibronectins - pharmacology | Genetic Predisposition to Disease | Human Umbilical Vein Endothelial Cells - drug effects | Atherosclerosis - physiopathology | Endothelial Cells - metabolism | Plaque, Atherosclerotic | Nitric Oxide Synthase Type III - genetics | Atherosclerosis - metabolism | Mice, Knockout | Nitric Oxide Synthase Type III - antagonists & inhibitors | Macrophages - metabolism | Phenotype | Signal Transduction - drug effects | Endothelium, Vascular - metabolism | Endothelium, Vascular - pathology | Human Umbilical Vein Endothelial Cells - pathology | Oxidative Stress - drug effects | Vasodilation - drug effects | Endothelial Cells - pathology | AMP-Activated Protein Kinases - genetics | AMP-Activated Protein Kinases - metabolism | Phosphorylation | Diabetic Angiopathies - pathology | Transfection | Nitric Oxide Synthase Type III - metabolism | Diabetes Mellitus, Experimental - metabolism | Diabetic Angiopathies - genetics | Diabetic Angiopathies - metabolism | Cytokines - metabolism | AMP-Activated Protein Kinases - antagonists & inhibitors | Mice, Inbred C57BL | Cells, Cultured | Endothelium, Vascular - physiopathology | Animals | Apolipoproteins E - genetics | Diabetes Mellitus, Experimental - pathology | Macrophages - drug effects | Protein Kinase Inhibitors - pharmacology | Atherosclerosis - prevention & control | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Endothelial Cells - drug effects | Insulin resistance | Diabetes | Apolipoproteins
Journal Article
Circulation journal : official journal of the Japanese Circulation Society, ISSN 1347-4820, 2013, Volume 77, Issue 5, pp. 1337 - 1344
Background: Dipeptidyl peptidase 4 (DPP4) inhibitors are used for treatment of diabetes mellitus (DM). We hypothesized that sitagliptin, a DPP4-inhibitor,... 
Dipeptidyl peptidase-4 inhibitors | Inflammation | Endothelial function | PROGENITOR CELLS | CARDIAC & CARDIOVASCULAR SYSTEMS | NITRIC-OXIDE SYNTHASE | ATHEROSCLEROSIS | AMPLITUDE | MELLITUS | PATHOPHYSIOLOGY | HEART-DISEASE | GLUCAGON-LIKE PEPTIDE-1 | CARDIOVASCULAR RISK | Multivariate Analysis | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Endothelium, Vascular - drug effects | Male | Pyrazines - therapeutic use | Coronary Artery Disease - blood | Diabetic Angiopathies - physiopathology | C-Reactive Protein - metabolism | Coronary Artery Disease - physiopathology | Time Factors | Diabetes Mellitus, Type 2 - immunology | Peripheral Arterial Disease - blood | Anti-Inflammatory Agents - therapeutic use | Female | Sitagliptin Phosphate | Odds Ratio | Diabetes Mellitus, Type 2 - complications | Endothelium, Vascular - immunology | Triazoles - therapeutic use | Manometry | Risk Factors | Endothelium, Vascular - physiopathology | Inflammation Mediators - blood | Peripheral Arterial Disease - drug therapy | Linear Models | Logistic Models | Treatment Outcome | Biomarkers - blood | Coronary Artery Disease - drug therapy | Diabetic Angiopathies - blood | Diabetic Angiopathies - drug therapy | Chi-Square Distribution | Peripheral Arterial Disease - physiopathology | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Peripheral Arterial Disease - immunology | Diabetic Angiopathies - immunology | Aged | Coronary Artery Disease - immunology | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
Molecular medicine (Cambridge, Mass.), ISSN 1528-3658, 2015, Volume 21, Issue S1, pp. S32 - S40
A nonenzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules and... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | POSITIVE ASSOCIATION | CELL BIOLOGY | FACTOR PEDF | ASYMMETRIC DIMETHYLARGININE GENERATION | SOLUBLE FORM | SERUM-LEVELS | NEUTRALIZING RAGE-ANTIBODY | ENDOTHELIAL GROWTH-FACTOR | Dipeptidyl Peptidase 4 - metabolism | Alzheimer Disease - complications | Oxidative Stress | Cardiovascular Diseases - drug therapy | Diabetes Mellitus, Type 2 - genetics | Humans | Glycation End Products, Advanced - antagonists & inhibitors | Osteoporosis - drug therapy | Diabetes Mellitus, Type 1 - complications | Cardiovascular Diseases - pathology | Cardiovascular Diseases - genetics | Alzheimer Disease - pathology | Neoplasms - complications | Cardiovascular Diseases - complications | Diabetic Angiopathies - pathology | Neoplasms - genetics | Diabetic Angiopathies - complications | Osteoporosis - genetics | Receptor for Advanced Glycation End Products - genetics | Diabetic Angiopathies - genetics | Diabetes Mellitus, Type 2 - complications | Gene Expression | Receptor for Advanced Glycation End Products - metabolism | Diabetes Mellitus, Type 1 - pathology | Alzheimer Disease - drug therapy | Diabetes Mellitus, Type 1 - genetics | Aptamers, Nucleotide - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Diabetic Angiopathies - drug therapy | Diabetes Mellitus, Type 1 - drug therapy | Neoplasms - drug therapy | Osteoporosis - pathology | Glycation End Products, Advanced - metabolism | Osteoporosis - complications | Diabetes Mellitus, Type 2 - pathology | Alzheimer Disease - genetics | Diabetes Mellitus, Type 2 - drug therapy | Neoplasms - pathology | Adenosine Deaminase Inhibitors - therapeutic use
Journal Article
The American journal of cardiology, ISSN 0002-9149, 2017, Volume 120, Issue 1, pp. S37 - S47
Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of heart failure in diabetes is very high, and the prognosis for... 
Cardiovascular | ALL-CAUSE MORTALITY | 2013 ACCF/AHA GUIDELINE | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | CARDIOVASCULAR OUTCOMES | CARDIAC METABOLISM | ASSOCIATION TASK-FORCE | GLUCOSE ABNORMALITIES | INDEPENDENT RISK-FACTOR | ATRIAL-FIBRILLATION | Hypoglycemic Agents - therapeutic use | Prevalence | Prognosis | Comorbidity | Humans | Heart Failure - physiopathology | Diabetic Angiopathies - drug therapy | Heart Failure - pathology | Diabetes Mellitus, Type 2 - epidemiology | Heart Failure - drug therapy | Incidence | Diabetic Angiopathies - physiopathology | Diabetes Mellitus, Type 2 - physiopathology | Diabetic Angiopathies - pathology | Diabetic Angiopathies - epidemiology | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - pathology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Heart failure | Type 2 diabetes | Periodical publishing | Diabetics | Cardiac patients | Pharmaceutical industry | Coronary heart disease | Risk factors | Glucose | Dextrose | Heart | Heart attacks | Cardiomyopathy | Cardiovascular disease | Metabolic syndrome | Epidemiology | Population | Heart diseases | Mortality | Diabetes mellitus | Coronary artery | Health risks | Hospitalization | Risk analysis | Coronary artery disease | Patients | Sodium | Medical prognosis | Coronary vessels | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 2017, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk... 
cardiovascular disease | DPP‐4 inhibitor | type 2 diabetes | diabetes complications | hypoglycaemia | dapagliflozin | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Original
Journal Article
Journal Article